Mankind Pharma Limited manufactures pharmaceutical products. It offers products in the areas of antibiotics, antifungals, gastrointestinals, anthelmintics, cardiovascular, dermal, ophthalmic, antibacterial, acute and chronic disease, antipsychotic, veterinary, antidiabetic, hypothyroidism, cough prepration, antimalarial, antimigraine, anti-viral, steriods, opthalmic, gynaecological, and anti-asthmatics. The company also provides consumer products, such as emergency contraceptives, pregnancy detection cards, antacids, condoms, sanitary napkins, body sprays, pregnancy test kits, toothbrushes, and sweeteners. It sells its products through a network of stockists and C&F agents. Mankind Pharma Li...
New Delhi, 110 020
Founded in 1991
Mankind Pharma Keen to Spend INR 5 Billion for Expansion in Local Market
Apr 11 15
Mankind Pharmaceuticals is ready to invest around INT 5 billion to acquire local pharma companies in order to strengthen its presence in the domestic market. The pharma company is not the sole candidate in this race as almost all the leading Indian pharma majors are adopting the same measure for their expansion.
Mankind Pharma Seeks Acquisitions
Apr 10 15
Mankind Pharma Limited is ready to invest around INR 5 billion to buy local rivals and is keen on licensing deals with foreign firms, a top official at the firm said. The company is also exploring buying established brands to expand its domestic footprint, Managing Director Sheetal Arora told Reuters in a phone interview. In scouting for local companies with niche capabilities, New Delhi-based Mankind would be competing with nearly all the top Indian pharma players, who are keen to expand domestically.
Mankind Pharma to Establish New Facility in Indian State of Rajasthan
Apr 7 15
Mankind Pharma announced that the company is constructing a manufacturing facility in Rajasthan, India. The facility will reportedly be used to manufacture active pharmaceutical ingredients (APIs) and is likely to become operational by the end of 2015. The facility is the result of a reported INR 1 billion investment. Further details of the facility have not been announced.